Evidence map›Paper›PMID 29858791›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

Imaging T Cell Dynamics and Function Using PET and Human Nuclear Reporter Genes.

Jason T Lee, Maxim A Moroz, Vladimir Ponomarev

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. OncoTargets and therapy · 2020
    Article
  3. Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason T LeeMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Maxim A MorozMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Vladimir PonomarevMemorial Sloan Kettering Cancer Center, New York, NY, USA. ponomarv@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survivalR01CA163980 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BLASBERG, RONALD GEORGE, PONOMAREV, VLADIMIR · 2012 to 2016
$2.5M
Imaging T-cell Activation and Co-stimulation in Prostate Cancer ImmunotherapyR01CA161138 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2011 to 2015
$1.9M
NanoSPECT/CT for Oncology ResearchS10RR028889 · NCRR · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2011 to 2011
$907k
SHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA086438NCI NIH HHS R01 CA161138NCI NIH HHS R01 CA163980NCI NIH HHS R01 CA204924NCRR NIH HHS S10 RR020892NCRR NIH HHS S10 RR028889
6 · The paper itself

Abstract

Adoptive cell transfer immunotherapy has demonstrated significant promise in the treatment of cancer, with long-term, durable responses. T cells expressing T cell receptors (TCRs) that recognize tumor antigens, or engineered with chimeric antigen receptors (CARs) can recognize and eliminate tumor cells even in advanced disease. Positron emission tomography (PET) imaging with nuclear reporter genes, a noninvasive method to track and monitor function of engineered cells in vivo, allows quantitative, longitudinal monitoring of these cells, including their expansion/contraction, migration, retention at target and off-target sites, and biological state. As an additional advantage, some reporter genes also exhibit "suicide potential" permitting the safe elimination of adoptively transferred T cells in instances of adverse reaction to therapy. Here, we describe the production of human nuclear reporter gene-expressing T cells and noninvasive PET imaging to monitor their cell fate in vivo.

Indexed as

Genes, ReporterAdoptive TransferAnimalsArabinofuranosyluracilHumansMiceMice, SCIDMolecular ImagingNuclear ProteinsPositron-Emission TomographyReceptors, Antigen, T-CellT-Lymphocytes2'-fluoro-2'-deoxy-5-fluoroethyl-1-beta-D-arabinofuranosyl uracilArabinofuranosyluracilNuclear ProteinsReceptors, Antigen, T-CellChimeric antigen receptorsHuman nuclear reporter geneImmunotherapyNucleoside kinasesPETReporter probeT cell

Identifiers

PMID29858791
PMCPMC9344925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.